COLL Q2 2020 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$78M+4.0% YoY

Gross Profit

$48M62.0% margin

Operating Income

$17M21.2% margin

Net Income

$8M10.3% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$43M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$647M

Total Liabilities

$491M

Stockholders' Equity

$156M

Cash & Equivalents

$146M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$75M	+4.0%
Gross Profit	$48M	$26M	+83.3%
Operating Income	$17M	-$5M	+430.5%
Net Income	$8M	-$5M	+271.0%

Revenue Segments

Nucynta

$45M36%

Xtampza

$34M27%

Nucynta Ir

$29M24%

Nucynta Er

$15M13%